Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Phase 1positivedarlifarnibadagrasibPositive

AI Analysis

Summary

Kura Oncology presented preliminary Phase 1a data showing darlifarnib in combination with adagrasib achieved objective response rates of 67% in pancreatic cancer, 50% in NSCLC, and 29% in KRAS inhibitor-naïve colorectal cancer, positioning the combination as a potential foundational platform for KRAS-mutant cancers.

Clinical Trial Data

Phase

Phase 1a

Primary Endpoint

Met

Outcome Details

Preliminary Phase 1a data from darlifarnib + adagrasib combination demonstrated confirmed objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients

Importance:6/10

Sentiment:

0.75

KRAS inhibitorscombination therapypancreatic cancernon-small cell lung cancercolorectal cancerobjective response rates

Related Companies

$KURA

Read the original article

Published by GlobeNewswire Pharma on June 3, 2026 10:53 AM

Read Original